Literature DB >> 16633366

Is there more to BARD1 than BRCA1?

Irmgard Irminger-Finger1, Charles Edward Jefford.   

Abstract

It has been over a decade since mutations in BRCA1 and BRCA2 were found to be associated with a small number of familial breast cancer cases. BRCA1 is a large protein that interacts with many other proteins that have diverse functions, so it has been a challenge to determine how defects in its function could lead to cancer. One particular protein, BARD1, seems to be an important regulator of the tumour-suppressor function of BRCA1, as well as acting as a tumour suppressor itself. BARD1 is indispensable for cell viability, so loss-of-function mutations are rare, but mutations and truncations that alter its function might be involved in the pathogenesis of breast cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16633366     DOI: 10.1038/nrc1878

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN: 1474-175X            Impact factor:   60.716


  51 in total

1.  Quantitative proteomic identification of the BRCA1 ubiquitination substrates.

Authors:  Meihua Song; Kevin Hakala; Susan T Weintraub; Yuzuru Shiio
Journal:  J Proteome Res       Date:  2011-10-11       Impact factor: 4.466

2.  Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences.

Authors:  David Fox; Isolde Le Trong; Ponni Rajagopal; Peter S Brzovic; Ronald E Stenkamp; Rachel E Klevit
Journal:  J Biol Chem       Date:  2008-05-14       Impact factor: 5.157

Review 3.  Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins.

Authors:  Ana C Magalhaes; Henry Dunn; Stephen Sg Ferguson
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

4.  Lack of association between BARD1 Cys557Ser variant and breast cancer risk: a meta-analysis of 11,870 cases and 7,687 controls.

Authors:  Da-Peng Ding; Ying Zhang; Wen-Li Ma; Xiao-Feng He; Wei Wang; Hai-Lang Yu; Yu-Bo Guo; Wen-Ling Zheng
Journal:  J Cancer Res Clin Oncol       Date:  2011-08-02       Impact factor: 4.553

5.  Characterization of LGALS3 (galectin-3) as a player in DNA damage response.

Authors:  Renato S Carvalho; Vanessa C Fernandes; Thales C Nepomuceno; Deivid C Rodrigues; Nicholas T Woods; Guilherme Suarez-Kurtz; Roger Chammas; Alvaro N Monteiro; Marcelo A Carvalho
Journal:  Cancer Biol Ther       Date:  2014-04-22       Impact factor: 4.742

6.  Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.

Authors:  Mario Capasso; Sharon J Diskin; Francesca Totaro; Luca Longo; Marilena De Mariano; Roberta Russo; Flora Cimmino; Hakon Hakonarson; Gian Paolo Tonini; Marcella Devoto; John M Maris; Achille Iolascon
Journal:  Carcinogenesis       Date:  2012-12-07       Impact factor: 4.944

7.  Tissue-specific target analysis of disease-associated microRNAs in human signaling pathways.

Authors:  Andreas Kowarsch; Carsten Marr; Daniel Schmidl; Andreas Ruepp; Fabian J Theis
Journal:  PLoS One       Date:  2010-06-30       Impact factor: 3.240

8.  BARD1 may be renamed ROW1 because it functions mainly as a REPRESSOR OF WUSCHEL1.

Authors:  Pei Han; Yu-Xian Zhu
Journal:  Plant Signal Behav       Date:  2009-01

9.  Decoding pooled RNAi screens by means of barcode tiling arrays.

Authors:  Michael Boettcher; Johannes Fredebohm; Amin Moghaddas Gholami; Yafit Hachmo; Iris Dotan; Dan Canaani; Jörg D Hoheisel
Journal:  BMC Genomics       Date:  2010-01-05       Impact factor: 3.969

10.  Common variations in BARD1 influence susceptibility to high-risk neuroblastoma.

Authors:  Mario Capasso; Marcella Devoto; Cuiping Hou; Shahab Asgharzadeh; Joseph T Glessner; Edward F Attiyeh; Yael P Mosse; Cecilia Kim; Sharon J Diskin; Kristina A Cole; Kristopher Bosse; Maura Diamond; Marci Laudenslager; Cynthia Winter; Jonathan P Bradfield; Richard H Scott; Jayanti Jagannathan; Maria Garris; Carmel McConville; Wendy B London; Robert C Seeger; Struan F A Grant; Hongzhe Li; Nazneen Rahman; Eric Rappaport; Hakon Hakonarson; John M Maris
Journal:  Nat Genet       Date:  2009-05-03       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.